INTRODUCTION
Essentially all physiological processes utilize intraand/or extracellular calcium (Ca2+) ions in some fashion. The intracellular free calcium concentration (Ca2+i) serves as a key intracellular second messenger and enzymic cofactor, regulating numerous critical cellular functions (i.e., muscular contraction, hormonal secretion, glycogen metabolism, cellular differentiation, prolifera- and regulation of neuromuscular excitability-further emphasizing the need for a mechanism maintaining near constancy of Ca2+o 3 .
Overview of the Ca2+o homeostatic system
Free-living terrestrial organisms have evolved a complex homeostatic mechanism that is responsible for the near invariance of Ca2+o in the blood (Figure 1 4 and indirectly (i.e., by inhibiting PTH release) and increases the secretion of CT. PTH and 1,25 (OH) 2D3 are the major Ca2+o-regulating hormones in humans, while calcitonin has little importance under normal physiological circumstances, although it may be useful in the therapy of certain disorders (e.g., Paget's disease). In response to hypocalcemia, increased circulating levels of PTH and 1,25 (OH)2D3 act on their various effector tissues, principally intestine, kidney and bone, and-by altering the transport of calcium ions into or out of the extracellular fluid--normalize Ca2+o ( Figure 1 ) [for review, see 3 ].
Thus the capacity of the cells secreting Ca2+o-regulating hormones to recognize and respond to small, physiologically relevant changes in Ca2+o is a crucial element in Ca2+o homeostasis. Changes in Ca2+o also, however, have direct actions on the cells that translocate Ca2+o into and out of the extracellular fluid--inhibiting, for example, distal tubular reabsorption of calcium 5 , promoting bone formation 6, 7 and inhibiting bone resorption 8, 9 . In effect, therefore, Ca2+o not only regulates the secretion of the classical Ca2+o-regulating hormones but also modulates their actions at the level of their target tissues and by directly regulating the latter. As described in more detail below, the cloning of a G protein-coupled receptor that mediates a number of these direct actions of Ca2+o-the Ca2+o-sensing receptor (abbreviated as CaR or CaSR)-demonstrates that Ca2+o, acting via the CaR, can itself be viewed as a Ca2+o-regulating hormone 3 . It does so both at systemic (i.e., by regulating PTH secretion) and local levels (i.e., by modulating renal tubular reabsorption of calcium) 10 . Indeed, Ca2+o can be viewed as the body's principal Ca2+o-lowering hormone.
Role of the G protein-coupled extracellular Ca2+-sensing receptor (CaR) in Ca2+o-sensing by parathyroid and diverse other cells.
Cloning and characteristics of the CaR
The use of expression cloning in Xenopus laevis oocytes enabled the isolation of a cDNA clone encoding a full length, biologically active CaR from a cDNA library prepared from bovine parathyroid 11 . The use of hybridization-based screening techniques then permitted the cloning of additional, highly homologous CaRs from human parathyroid ( Figure 2 ) and kidney, as well as from rat kidney, C-cell, and brain [for review, see 3 .
These various CaRs are all activated not only by high Ca2+o but also by Mg2+o and diverse inorganic [e.g., the trivalent cation, gadolinium (Gd3+)] and organic polycations (i.e., spermine and neomycin) 11 . Ca2+o, and perhaps Mg2+o, are thought to be the physiologically relevant agonists of the receptor in vivo, although it is possible that spermine, when present in certain locations within the body at sufficiently high levels, could also modulate the CaR 12 . The CaR has three major structural features that can be predicted from its deduced amino acid sequence (Figure 2 ): 1) A large (~600 amino acid) amino-terminal extracellular domain (ECD) that plays an important role in sensing Ca2+o, 2) seven membrane-spanning helices that are the signature of the GPCRs and 3) an intracellular C-terminal tail of some 200 amino acid residues 13 . The CaR's C-tail as well as its intracellular loops likely play important roles in coupling the receptor to its intracellular effector systems, in a G protein-dependent manner 14 . The latter include CaR-mediated activation of phospholipases C, D and A2 15 as well as various mitogenactivated protein kinases (MAPK) 16, 17 , and inhibition of adenylate cyclase 18 .
Tissue distribution of the CaR
The CaR is expressed at the highest levels in parathyroid cells, C-cells 19, 20 as well as in the distal tubule of the kidney 21 , and its functional roles in these tissues is discussed below (for review, see 3 ). The receptor is also expressed at lower levels in other nephron segments (e.g., the proximal tubule and distal collecting duct) 21 , along the entire length of the gastrointestinal tract 22 , as well as within growth plate cartilage 23 , osteoblastic cell lines 24 and osteoblasts within sections of bone 23 (although some investigators have not detected the receptor in osteoblastic cells 25 ). It is also expressed in cells of the monocyte/macrophage lineage that could potentially serve as osteoclast precursors 26 . There is conflicting evidence as to whether it is present in osteoclasts or if Ca2+o-sensing in this cell type as well as in osteoblasts involves the CaR or some other molecular mechanism, as will be discussed in more detail later (for review, see 3 ); its physiological relevance in the GI tract likewise remain uncertain.
The receptor is also expressed, however, in numerous tissues that are almost certainly uninvolved in Ca2+o homeostasis (for review, see 3 ). For instance, in the intestine, the CaR is expressed in the surface cells of the gastric mucosa and widely throughout the enteric nervous system. Within the kidney, the CaR is present on the apical membrane of the inner medullary collecting duct, where it probably mediates the known inhibitory action of elevated Ca2+o on vasopressin-stimulated water reabsorption (see below) 27 . In bone marrow, the CaR is expressed in several hematopoietic lineages, particularly red blood cell precursors, megakaryocytes and monocytes. Other non-homeostatic tissues that express the receptor include the epithelial cells of the breast ducts, keratinocytes, pancreas, various cell types within the central nervous system (e.g., hippocampal pyramidal, cerebellar and numerous other neurons as well as oligodendrocytes), lens epithelial cells and numerous others. Clearly a great deal remains to be learned about the receptor's roles in these tissues, although it may respond to local changes in Ca2+o in ways that enable it to participate in their normal differentiated functions.
Control of parathyroid function and CT secretion by the CaR
Strong evidence supports the CaR's role in mediating of the inhibitory actions of Ca2+o on PTH release and parathyroid cellular proliferation. The CaR's importance in controlling PTH secretion is supported by the abnormalities in Ca2+o-regulated PTH release that are present in inherited human diseases with inactivating or activating mutations 28 in the receptor and mouse models in which the CaR has been knocked out 29 . As described in more detail below, in human disorders in which the receptor has reduced activity as well as in mice with targeted disruption of one allele of the CaR gene, there is impaired inhibition of PTH secretion at any given level of Ca2+o. In contrast, in patients with CaRs that are overly sensitive to activation by Ca2+o due to the presence of activating mutations, there is a greater than normal suppression of hormonal secretion as a function of Ca2+o. In both humans who are homozygous for inactivating mutations of the CaR or in mice homozygous for knockout of the CaR gene, there is not only markedly abnormal Ca2+o-regulated PTH release but also substantial parathyroid gland hyperplasia 28, 29 , strongly supporting the CaR's role in tonically inhibiting parathyroid cellular growth. The CaR may also mediate other known actions of Ca2+o on parathyroid function, including inhibition of PTH gene expression 30 , although additional studies are needed in this regard. Despite intensive study over several decades the major intracellular mediators of the CaR's actions on PTH secretion and other aspects of parathyroid function remain uncertain 31 . As noted above, the CaR is expressed at high levels in the C-cells of the thyroid gland 19, 20 . Available evidence supports its involvement in activating signal transduction pathways that increase Ca2+i and stimulate CT secretion unlike the parathyroid cell in which CaR-induced increases in Ca2+i are associated with inhibition of PTH secretion 32 .
Control of renal function by the CaR
Several lines of evidence suggest that the CaR plays a key role in controlling Ca2+ and Mg2+ reabsorption in the renal distal tubule and represents the molecular mechanism for the direct inhibitory actions of Ca2+o and Mg2+o on divalent cation reabsorption in this portion of the nephron 33 . The CaR is expressed at high levels on the basolateral surface of the epithelial cells of the cortical thick ascending limb (CTAL) of the nephron 21 , where, as in parathyroid cells, it appears to couple to activation of PLA2 and inhibition of adenylate cyclase (for review, see 3 ). The inhibitory, presumably CaR-mediated action of elevated Ca2+o on divalent cation reabsorption in CTAL is thought to result from a reduction in the reabsorption of sodium chloride by the NaK2Cl cotransporter that is coupled, in turn, to a concomitant decrease in tubular reabsorption of Ca2+ and Mg2+ via the paracellular pathway 33 . The CaR, in effect, acts like a loop diuretic, although it inhibits the cotransporter indirectly rather than directly as in the case with the diuretics 33 . This direct, local action of Ca2+o on tubular function likely provides a mechanism for local autoregulation of divalent cation handling by the CTAL in addition to the modulating the known stimulatory action of circulating PTH on this parameter (e.g., Figure 1 ).
In addition to their abnormal Ca2+o-regulated PTH secretion, patients with inactivating mutations of the CaR also exhibit overly avid renal tubular Ca2+ and Mg2+ reabsorption 34 . The latter presumably results from a reduced number of normally functioning CaRs in the CTAL, leading to resistance to the usual action of hypercalcemia to promote calciuria. Interestingly, the only maneuver that substantially increases urinary calcium excretion in these patients is administering the loop diuretic, ethacrynic acid 35 . This observation adds additional indirect evidence that defective CaR-mediated inhibition of the NaK2Cl cotransporter participates in their excessive tubular reabsorption of divalent cations. The CaR is also expressed in the distal convoluted tubule, another important site where PTH increases distal tubular reabsorption of calcium, but its functional role in this nephron segment requires additional investigation. It should be possible to use the mouse model with targeted disruption of the CaR to investigate further the role of the CaR in regulating divalent cation handling as well as other aspects of renal function.
Does the CaR regulate the functions of intestinal and bone cells?
The CaR's presence in the epithelial cells of the small and large intestines that are involved in calcium absorption suggests that it could potentially be involved in regulating this process 22 . Its presence in the enteric nervous system could also implicate it in controlling intestinal secretomotor functions 22 . However, there is no direct evidence that the receptor regulates these functions, and additional studies are needed.
Ca2+o is known to stimulate various aspects of osteoblastic function, such as proliferation, chemotaxis, and the secretion of growth factors as well as bone formation per se in organ culture (for review, see 24 ). Ca2+o also inhibits various aspects of osteoclastic function 9 . Whether the receptor mediates the functions of these bone cells, however, remains an open question. Some investigators have found the CaR to be expressed in osteoblastic cell lines, bone marrow stromal cells or in bone sections and to regulate some aspects of osteoblast function 9, 23 , but others have not been able to demonstrate the receptor's presence in cells of the osteoblastic lineage 25 . Furthermore, the latter investigators found that osteoblastic cells from CaR knockout mice could still respond to changes in Ca2+o 36 . There is also controversy as to whether the CaR is in osteoclasts and/or their precursors and mediates known actions of Ca2+o on cells of the osteoclast lineage (for review, see 24 ). The CaR is expressed at readily detectable levels in blood monocytes, which include cells that can serve as osteoclast precursors, and mediates the chemotactic response of these cells to elevated levels of Ca2+o 26 . Some but not all investigators have documented CaR expression in mature, multinucleated osteoclasts 24, 37 . Again, however, more di-rect evidence is needed, particularly in view of the fact that there are pharmacological differences between the putative Ca2+o-sensors/receptors in osteoblasts and osteoclasts and the CaR 9 . Nevertheless, the capacity of bone cells to sense Ca2+o likely enables direct, local actions of Ca2+o on the functions of these cells that contribute additional homeostatic control to that afforded by more classical calciotropic hormone (e.g., PTH and 1,25 (OH) 2D3) 7, 24 .
Roles of the CaR in integrating mineral ion homeostasis with other homeostatic systems
Hypercalcemic patients can manifest defective maximal urinary concentrating ability and, on occasion, overt nephrogenic diabetes insipidus 10, 28 . The presence of the CaR in nephron segments that participate in urinary concentration (e.g., the inner medullary collecting duct) has provided novel insights into how high Ca2+o may regulate the renal concentrating mechanism 27 . Perfusion of the lumen of IMCD tubules from rat kidney with high Ca2+o reversibly inhibits vasopressin-evoked transepithelial water flow. In addition, the CaR is present in the same apical endosomes in cells of the IMCD that contain the vasopressin-regulated water channel, aquaporin-2 27 . Therefore, the CaR could diminish vasopressin-activated water flow in the IMCD by decreasing the availability and/or the activity of the aquaporin-2 water channels in the apical membrane. CaR-induced reduction in NaCl reabsorption in the loop of Henle would also act to reduce the medullary countercurrent gradient, which would further decrease maximal urinary concentrating ability in hypercalcemic individuals. Of interest in this regard, patients with FHH concentrate their urine normally 38 , while those who harbor activating mutations of the CaR can develop symptoms of defective urinary concentration at normal or even subnormal blood calcium concentrations 39 , presumably because the former are resistant and the latter excessively sensitive to the actions of elevated Ca2+o on urinary concentration.
Thus it is possible that the CaR may provide a means of integrating divalent cation and water handling by the kidney in order to allow appropriate trade-offs in the regulation of these aspects of renal function that are appropriate for specific physiological circumstances. For instance, in circumstances when a systemic calcium load must be disposed of, coordinating the CaR-induced increase in urinary Ca2+ concentration owing to reduced calcium reabsorption in the CTAL with the associated decrease in maximal urinary concentrating capacity would diminish the maximal level of luminal Ca2+o in the IMCD. This could reduce the risk of Ca2+ stone formation 10 . The CaR is also expressed at high levels in the subfornical organ (SFO), an important thirst center in the hypothalamus 40 . High Ca2+o-evoked, CaR-mediated thirst and increased drinking could prevent dehydration otherwise resulting from renal free water loss owing to CaR-mediated renal resistance to vasopressin. Thus there may be multiple levels of integration of the homeostatic control systems for calcium and water metabolism, which may optimize the ability of free-living terrestrial organisms to adapt to their intermittent access to dietary calcium and water.
Recent studies have also shown that the CaR is activated by various amino acids, particularly aromatic amino acids, in the presence but not in the absence of physiologically relevant levels of Ca2+o (i.e., 1 mM) 41 . The presence of a mixture of amino acids emulating that present in the blood can sensitize the receptor significantly to Ca2+o 41 . This multimodal sensing by the CaR of both Ca2+o and amino acids may contribute to some of the known but poorly understood interactions between protein and calcium metabolism. For instance, high protein intake induces hypercalciuria and reduced protein intake produces substantial increases in circulating PTH levels in normal individuals (for review, see 42 ). Further studies of the CaR's participation in integrating mineral ion and protein metabolism may provide novel insights into how coordination of these homeostatic processes could contribute to processes involving the need for both mineral ions and protein, such as skeletal and somatic growth.
DISORDERS OF CALCIUM HOMEOSTASIS ARISING FROM ABNORMALITIES IN THE CAR Disorders with generalized resistance to Ca2+o
The availability of the cloned CaR made it possible to search for disorders of mineral ion homeostasis resulting from abnormal structure and/or function of the CaR. Earlier studies had suggested that the autosomal dominant hypercalcemic disorder, familial hypocalciuric hypercalcemia (FHH), exhibited features consistent with generalized Ca2+o-resistance 34, 43 . Despite their hypercalcemia, patients with FHH exhibit few, if any, of the usual symptoms, signs and complications of hypercalcemia. In addition, patients with FHH exhibit signs of resistance to the usual actions of hypercalcemia on parathyroid and kidney 34, 44 : (1) Their serum PTH levels are inappropriately normal or mildly elevated in the face of hypercalcemia, consistent with resistance of the parathyroid to Ca2+o. Indeed, they exhibit an increase in the set-point for Ca2+o-regulated PTH release (the level of Ca2+o half-maximally suppressing circulating PTH levels) 45, 46 . (2) They exhibit inappropriately normal or even low levels of renal tubular Ca2+ reabsorption given their hypercalcemia 34, 43 . This abnormality in renal tubular Ca2+ handling persists even following complete parathyroidectomy, demonstrating that it is an intrinsic renal tubular defect and not the result of impaired high Ca2+o-induced suppression of PTH release 35, 47 . (3) Finally, patients with FHH concentrate their urine normally in spite of their hypercalcemia, suggesting resistance to the normal inhibitory effect of hypercalcemia on the urinary concentrating mechanism 38 .
Another feature of FHH distinguishing it from PHPT is the unusual clinical course following parathyroidectomy. Unlike patients with PHPT, in whom parathyroidectomy usually produces long term cure of the hypercalcemia, performing anything less than total parathyroidectomy in persons with FHH is followed within a matter of days to weeks by recurrence of hypercalcemia 34 . From a clinical perspective, therefore, it is important to differentiate FHH from PHPT. Not only are individuals with the former condition generally asymptomatic, so that parathyroid surgery is of no apparent benefit, but it also generally fails to produce long term remission of hypercalcemia in FHH without inducing hypoparathyroidism. The general consensus has evolved, therefore, that persons with FHH should not undergo parathyroidectomy 34, 43, 48 . In occasional families with FHH, however, there can be overt hypercalciuria and even renal stones 49 or the hypercalcemia can be quite severe (e.g., 13-14 mg/ dl) 50 , and surgical therapy in these patients could potentially be of benefit. No doubt the clinical spectrum of FHH will enlarge further as our capacity to make a molecular diagnosis (see below) identifies more families with this condition.
The most helpful clinical clues to the diagnosis of FHH are as follows: (1) The presence of generally mild to moderate hypercalcemia (and, sometimes, mild hypermagnesemia) with an autosomal dominant pattern of inheritance, (2) intact PTH levels within the normal range and (3) relative hypocalciuria 34, 43, 51 . A useful way to document the abnormal renal Ca2+ handling is to calculate the ratio of the urinary calcium clearance to that for creatinine (the calcium to creatinine clearance ratio) 34 . Most patients with FHH will exhibit a value of 0.01 or less, while about 80% of patients with PHPT will have a value above 0.01. The diagnosis of FHH can in most cases be documented on the basis of these clinical and biochemical features and does not require genetic analysis to identify the mutations in the CaR that have subsequently been proven to be the cause of the vast majority of cases of this disorder 51 .
The gene for FHH was shown to reside on the long arm of chromosome 3 in 1992 52 , although in rare families a biochemically similar disorder was also found to be linked to two different loci on chromosome 19 53, 54 , documenting the genetic heterogeneity of this condition. Not long after the cloning of the CaR, three families with this condition were shown to harbor heterozygous missense mutations (i.e., a single base changes substituting a different amino acid for the one normally coded for) in the CaR's coding region 55 . Subsequent studies by a number of laboratories have identified several dozen more missense mutations, occasional nonsense (e.g., mutation of a codon that encodes an amino acid to a stop codon) or other types of mutations in the CaR genes in FHH families, some of which are shown in Figure 2 [for review, see 51 ]. When expressed in heterologous systems, such as human embryonic kidney (HEK) cells, these mutations produce varying degrees of inactivation of the CaR--varying from modest reductions in its apparent affinity for Ca2+o to its complete loss of function (Figure 3) 56,57 .
Therefore, reduction or loss of the normal function of one allele of the CaR gene produces a disorder with mild, generalized resistance of CaR-expressing tissues to Ca2+o. In the parathyroid, the resultant, modest (10-20%) increase in set-point is a major contributor to resetting the mineral ion homeostatic system to maintain a higher than normal Ca2+o. In the kidney, resistance to Ca2+o has two apparent consequences-(a) increasing the set-point of the kidney for high Ca2+o-evoked increases in urinary calcium excretion and (b) reducing the impairment of urinary concentration observed for a given degree of hypercalcemia [for review, see 51 ]. This hypothesis is supported by a mouse model of FHH generated by targeted disruption of the CaR gene 29 . Mice heterozygous for CaR knock-out exhibit mild hypercalcemia (10.4 mg/dl), with normal PTH levels of PTH and relative hypocalciuria 29 . These mice appear otherwise well, resembling, therefore, patients with FHH. Mice homozygous for inactivation of the CaR gene, in contrast, have much more severe hypercalcemia (~15 mg/dl), accompanied by 5-10-fold elevations in PTH, severe bony demineralization and frequent fractures owing to severe hyperparathyroid bone disease 29 . They uniformly die within the first few weeks of life.
The clinical and biochemical findings in mice homozygous for knockout of the CaR resemble in many ways those of infants with neonatal severe hyperparathyroidism (NSHPT). Early descriptions of NSHPT emphasized these infants' severe hypercalcemia (levels as high as 30.8 mg/dl have been reported) as a result of marked hyperparathyroidism due to four gland parathyroid hyperplasia 48, 58 . These infants often had multiple fractures resulting from hyperparathyroid bone disease. These early studies generally recommended complete or subtotal parathyroidectomy as the treatment of choice for NSHPT, as the disorder was often fatal without surgical intervention in these early reports 48, 58 . More recent reviews have documented a wider clinical spectrum for infants with NSHPT 48 . A substantial proportion of cases exhibit hyperparathyroid bone disease or bony demineralization accompanied by a milder degree of hypercalcemia (e.g., 12-14 mg/dl) 48 . In these cases, the condition is often self-limited with conservative medical therapy, and the clinical picture eventually reverts within several months to one that is not unlike FHH 48 . In fact, many of these infants have been found to be members of FHH kindreds 48, 58 .
The cloning of the CaR and the demonstration that FHH is the result of heterozygous inactivating mutations of the CaR gene has subsequently elucidated the molecular basis for several cases of NSHPT. The most severe cases, usually with serum calcium concentrations of 14-16 mg/dl or higher, can represent FHH in its homozygous form (i.e. both alleles of the CaR gene harbor inactivating mutations) 59 as a result of consanguineous marriages of two affected individuals. A more recently described infant with severe NSHPT was shown to be a compound heterozygote as a result the marriage of two individuals with different mutations in the CaR 60 . These cases of NSHPT due to homozygous or compound heterozygous CaR mutations usually require parathyroidectomy to avoid severe complications including death.
It is also apparent, however, that in many cases of NSHPT only one parent has clinically apparent FHH 48, 58 . In some cases, the disorder may result, at least in part, from FHH mutations that exert dominant negative actions on the remaining normal CaR allele 61 . Because the active, cell surface form of the CaR is a dimer 62 , this dominant negative action likely results from the formation of CaR heterodimers -containing one wild type and one mutant CaR molecule-that have a reduced capacity to be activated over the normal range of Ca2+o. As a result, homodimeric CaRs containing two normal receptors would comprise on a purely statistical basis only 25% of the cell surface receptors and would represent the only species of the CaR on the cell surface with normal biological activity. Therefore, the resistance of parathyroid and kidney to Ca2+o in such cases would be greater than in the mouse model of FHH or in FHH families with mutations that are not expressed efficiently on the cell surface, because in the latter instances normal receptors (e.g., arising from the remaining normal allele of the CaR gene) would comprise closer to 50% of the cell surface CaR 51 . Indeed, in FHH families with mutations exerting dominant negative actions in vitro (e.g., R795W and R185Q), the hypercalcemia in affected family members is more severe (12.5 and 13-14 mg/dl, respectively) than in the majority of FHH families (~10.5-11.5 mg/dl) 61 . In addition, several affected infants in the family harboring the R185Q mutation presented with NSHPT 50 , even with only one affected parent. Similarly, a recently described infant with the same R185Q mutation 61 proved to have arisen de novo, since both biological parents were unaffected. Several other infants have subsequently been described with de novo mutations causing NSHPT 63 . In these cases, it may be prudent to perform mutational analysis to confirm the diagnosis. In general, in most cases of NSHPT due to heterozygous CaR mutations, conservative medical therapy of the hypercalcemia will produce a successful clinical outcome if the serum calcium concentration is not excessively elevated (i.e., >15 mg/dl) and if parathyroidectomy is not deemed necessary on purely clinical grounds. Each case should be carefully evaluated on an individual basis, however, to minimize complications and to preclude the occasional fatal outcome in severely affected infants.
Disorders resulting from "tissue-specific" Ca2+o-resistance
In primary and some cases of uremic secondary hyperparathyroidism (usually when there is overt hypercalcemia) -in contrast to FHH and NSHPT where there is generalized resistance to Ca2+o-the resistance to Ca2+o is present solely in the pathological parathyroid gland(s) [for review see 51 ] , while all other tissues in the body presumably have normal sensitivity to Ca2+o. Parathyroid cells prepared from pathological parathyroid tissue of patients with primary and severe uremic hyperparathyroidism have ~20-30% increases in their set-points for Ca2+o-regulated PTH release 51 , which is slightly higher than the elevation in set-point in FHH. Several studies have recently shown ~50% reductions in the levels of expression of CaR mRNA and/or protein in such pathological parathyroid glands relative to normal parathyroid tissue [for review, see 51 ], without any mutations in the CaR's coding region 64 . This reduced expression of the CaR may result from reduced activity of one of the two functional promoters of the CaR gene 65 . Thus the resistance of the parathyroid glands to Ca2+o in hyperparathyroidism as well as in FHH and NSHPT have in common a reduced complement of normal CaRs on the parathyroid cell surface.
A disorder resulting from generalized over responsiveness to Ca2+o
Because activating mutations in other GPCRs can cause disease 66 , such as hyperthyroidism caused by activated mutant TSH receptors 67 , it seemed possible that a disorder might exist that was the mirror image of FHH in other words, familial hypercalciuric hypocalcemia. Indeed, screening of families with autosomal dominant hypocalcemia for mutations in the CaR has revealed well over a dozen families harboring activating mutations 39, 68, 69 (for review, see 28 ). Individuals with activating mutations of the CaR may be asymptomatic, but they not infrequently exhibit symptoms present in other hypocalcemic disorders, including carpopedal spasm and/or seizures, particularly in those with more severe hypocalcemia. Affected individuals manifest mild to moderate and, in some cases, severe (5-6 mg/dl) hypocalcemia accompanied by normal to frankly elevated levels of serum phosphorus, and frankly low or low-normal levels of PTH. In the untreated state, these patients tend to have higher rates of urinary calcium excretion than do patients with hypoparathyroidism of other causes 69 , which can increase dramatically during treatment with calcium and vitamin D supplementation 39 . Some families also have hypomagnesemia 39 , although serum magnesium concentrations have not been reported in many families. De novo activating CaR mutations have also been described as a cause of sporadic hypocalcemia, emphasizing the importance of considering this diagnosis even in the absence of familial involvement 69 .
Expression of mutant CaRs engineered to contain activating mutations has revealed increases in the apparent affinities of these receptors for Ca2+o 39 ( Figure 3 ). Most of these mutations reside within the CaR's ECD, emphasizing its importance in the mechanism of receptor activation following ligand binding, although some mutations are present within the CaR's transmembrane domains, the most common location for naturally-occurring activating mutations of other GPCRs 66 . These activating mutations reset the calcium homeostatic system downward such that it defends a stable, albeit lower than normal level of Ca2+o. Thus, analogous to FHH, autosomal dominant hypocalcemia owing to activating CaR mutations is a disorder in which the calciostat is resetupward in the case of FHH and downward with activating mutations. Nevertheless, autosomal dominant hypocalcemia due to activating CaR mutations resembles hy-poparathyroidism clinically in the sense that there is insufficient PTH to maintain normocalcemia.
Treatment of hypocalcemia resulting from activating mutations should be limited to symptomatic patients, because of their tendency to develop renal complications during treatment with vitamin D and calcium supplementation, which can produce severe hypercalciuria, nephrocalcinosis, renal stones and impaired renal function 39 . The hypercalciuria of patients with activating mutations in the untreated state as well as during treatment is almost certainly the result of activated CaRs in the kidney that reduce renal tubular Ca2+ reabsorption the opposite of the abnormality in renal Ca2+ handling observed in FHH. During treatment with vitamin D and calcium supplementation, therefore, urinary calcium excretion in addition to serum calcium concentration should be monitored carefully to avoid renal complications. The serum calcium concentration should be raised just enough to alleviate symptoms without producing excessive hypercalciuria. In some cases it may be necessary to use a thiazide diuretic to reduce urinary calcium excretion if symptoms persist in the presence of overt hypercalciuria during treatment with calcium and vitamin D supplementation.
In summary, it is important to consider the diagnosis of an activating CaR mutation in patients with what appears to be hypoparathyroidism but occurs in association with varying combinations of the following constellation of findings: (a) low-normal levels of serum PTH in the untreated state, (b) hypomagnesemia, (c) the occurrence of hypocalcemia in other family members with an autosomal dominant pattern of inheritance and (d) a tendency to hypercalciuria in the untreated state as well as marked hypercalciuria that is accompanied by impaired renal function, nephrolithiasis and/or nephrocalcinosis during treatment with vitamin D and calcium supplementation. In sporadic cases with these findings, mutational analysis may be appropriate to establish the diagnosis, although it is not available on a routine basis. Only symptomatic patients should be treated, and they should be monitored carefully during treatment with regular determinations of serum and urinary calcium concentrations to avoid renal complications.
CAR-BASED THERAPEUTICS
The CaR potentially represents an important therapeutic target for diseases in which the receptor is inappropriately over-or underactive 70 . To date CaR-based therapy has been directed principally at primary and uremic hyperparathyroidism 71, 72 . Clinical trials are currently ongoing that are addressing the efficacy of the so-called calcimimetic CaR activators in the treatment of primary and uremic hyperparathyroidism. These agents produce rapid (within minutes) and substantial (>50%) decreases in circulating PTH, followed several hours later by reductions in serum calcium concentration at higher doses. When administered for several months calcimimetics can normalize serum calcium and PTH concentrations in most patients without promoting hypercalciuria, suggesting that they activate the CaR in the parathyroid to a greater extent than that in the kidney. In effect, the calcimimetics reset the elevated set-point of patholo-gical parathyroid glands toward normal 73 . CaR agonists will likely also be very useful for treating uremic hyperparathyroidism. Available data suggest that they lower the calcium-phosphate product as well as serum PTH levels, thereby providing an effective means of treating or mitigating the complications associated with abnormal mineral ion metabolism in renal failure 72 . CaR antagonists, so-called calcilytics, are available and are under investigation as a means of stimulating PTH secretion in an intermittent fashion, which might represent an alternative approach to the administration of exogenous PTH in the treatment of osteoporosis 74 .
SUMMARY AND CONCLUSIONS
Our understanding of the molecular basis for Ca2+o-sensing has increased greatly since the cloning of the G protein-coupled, Ca2+o-sensing receptor. The receptor plays a key role in maintaining the near constancy of Ca2+o through its actions the effects of Ca2+o on PTH secretion and renal calcium reabsorption. Ca2+o-sensing by the CaR or some other mechanism may also modulate the functions or intestinal and/or bone cells in ways that are physiologically relevant. The CaR also appears to participate in integrating Ca2+o homeostasis with other homeostatic systems (e.g., those regulating water and protein metabolism). The identification of inherited diseases of Ca2+o-sensing resulting from inactivating or activating mutations in the receptor has provided proof of the central role of the CaR in calcium homeostasis, as has the development of a mouse model with knockout of the CaR gene. Finally, CaR-based therapeutics that allosterically activate the receptor will likely provide the first truly effective medical treatment for primary and uremic secondary hyperparathyroidism and antagonists of the CaR also exhibit therapeutic promise.
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